Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Beyond Meat Inc (BYND) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Beyond Meat Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $287 (market cap $39.89B), while Beyond Meat Inc trades at $0.63 (market cap $338.06M). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 118× Beyond Meat Inc's market cap. Which is the better fit depends on your goals.
| ALNY | BYND | |
|---|---|---|
Market Cap | $39.89B | $338.06M |
Sector | Health | Consumer Staples |
52-Week High | $491.22 | $4.28 |
52-Week Low | $278.09 | $0.52 |
Enterprise Value | $38.15B | $648.06M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
BYND trades at $0.656, down 2.77% today, with a bearish technical signal from moving averages. The company shows mixed fundamentals with a net income margin of 79.49% but negative operating cash flow of -$144.93M in 2025. Recent product expansions include Beyond Steak Filet at Meijer and Wegmans, while earnings have been volatile with two misses and one beat in the last four quarters.
The outlook remains challenging with 57% analyst sell ratings and declining revenue trends. Key risks include persistent cash burn and competitive pressures. Upside potential hinges on successful turnaround efforts through new product launches and cost management, but the stock faces significant headwinds near current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Beyond Meat Inc
Beyond Meat is a provider of plant-based meats, such as burgers, sausage, ground beef, and chicken. Unlike other vegetarian products, Beyond Meat seeks to replicate the look, cook, and taste of meat, is targeted to omnivores and vegetarians alike, and is sold in the meat case. The products are widely available across the U.S. and Canada and in 83 additional countries as well. International revenue represented 31% of 2021 sales. The firm's products are available in retail stores and the food-service channel. In 2019, before the pandemic struck, sales were evenly split between these two channels, although mix stood at 70% retail/30% food service in 2021. We think the recovery from the crisis and new deals with McDonald's and Yum Brands will return food-service sales to nearly 50% in time.
Read more on BYND →
